The role and efficacy of Bimekizumab

Bimekizumab is a monoclonal antibody that selectively inhibits interleukin (IL)-17A and IL-17F. It is currently being studied for the treatment of moderate to severe plaque psoriasis. For psoriasis, maintenance dosing of IL-17 inhibitors every 4 weeks is well established. Inhibition of IL-17F in addition to IL-17A resulted in rapid and profound clinical responses. Furthermore, profound normalization of keratinocyte biology and psoriasis transcriptome was observed, including normalization of IL17 and IL23 gene expression at week 8.

At Week 8, 47% of patients achieved 100% improvement from baseline in the Psoriasis Area and Severity Index (PASI 100), which increased to 57% at Week 12 (8 weeks after the second dose) and then declined. Among patients who received bimeclizumab at week 16, the PASI 100 ratio increased to comparable peak levels at week 20 but decreased to 41% at week 28 (12 weeks after the third dose). The transcriptional signature observed in lesional psoriatic skin at week 8 rapidly normalized to levels consistent with nonlesional skin, leading to molecular remission. Keratinocyte-associated gene products, such as CXCL1 (C-X-C motif chemokine ligand 1), IL-8 (encoded by the CXCL8 gene), CCL20 (C-C motif chemokine 20), IL-36γ, and IL-17C, were fully normalized to levels associated with non-injured skin.

The generic drug Bimeizumab has not yet been launched in the country, so it cannot be included in medical insurance. The European version of bimezumab original drug sold overseas, specifications160mg*2 per box may cost more than 40,000 yuan (the price may fluctuate due to the exchange rate). The price is still relatively high. There is currently no generic version of bimezumab produced and launched. For the specific price and drug information of this drug, please consult a medical consultant.